Endometrial Cancer Clinical Trials in Atlanta, Georgia
9 studies are recruiting for endometrial cancer in Atlanta, Georgia right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.
Search these by distance from you
Studies now recruiting
-
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
This protocol tests de-escalated adjuvant treatment in patients with POLE-mutated or p53wt/NSMP (p53 wildtype/no specific molecular profile) early-stage endometrial cancer (EC). Patients may be enrolled in one of two sub-studies * EN10.A/RAINBO BLUE: POLE-mutated EC * EN10.B/TAPER: p53 wildtype / N…
- Stage
- Phase 2
- Ages
- 18 and older
- Site
- Grady Health System, Atlanta, Georgia
- Locations
- 121 in total
- Run by
- Canadian Cancer Trials Group
-
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
The purpose of this study is to compare how well Rina-S (GEN1184) works compared to treatment of physician's choice (paclitaxel or doxorubicin) that are considered standard medical care for the treatment of recurrent or progressive endometrial cancer (EC) following prior therapy. There is an equal …
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- Emory Winship Cancer Inst., Atlanta, Georgia
- Locations
- 171 in total
- Run by
- Genmab
-
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 on tumor outcomes.
- Stage
- Phase 1
- Ages
- 15 and older
- Site
- Winship Cancer Institute, Emory University, Atlanta, Georgia
- Locations
- 22 in total
- Run by
- Xencor, Inc.
-
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy and in combination with enzalutamide, in patients with advanced solid t…
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Winship Cancer Institute of Emory University, Atlanta, Georgia
- Locations
- 80 in total
- Run by
- Novartis Pharmaceuticals
-
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
A Study of Emi-Le in Participants with Solid Tumors
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Winship Cancer Institute, Emory University, Atlanta, Georgia
- Locations
- 26 in total
- Run by
- Day One Biopharmaceuticals, Inc.
-
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
The overarching objective of this project is to develop a pan-gynecologic cancer detection test using gynecologic (unique endometrial, cervical, and ovarian cancer) cancer-specific methylated DNA markers and high-risk human papilloma virus (HR-HPV) detected in vaginal fluid and/or plasma. This prop…
- Stage
- Not phased
- Ages
- 18 and older
- Site
- Piedmont Healthcare, Atlanta, Georgia
- Locations
- 24 in total
- Run by
- Mayo Clinic
-
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…
- Stage
- Not phased
- Ages
- Any age
- Site
- Massive Bio SYNERGY-AI site, Atlanta, Georgia
- Locations
- 68 in total
- Run by
- Massive Bio, Inc.
-
A Beta-only IL-2 ImmunoTherapY Study
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Emory - Winship Cancer Institute, Atlanta, Georgia
- Locations
- 27 in total
- Run by
- Medicenna Therapeutics, Inc.
-
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
This study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (EC) who have achieved complete response or partial response on chemotherapy. The study will be conducted in 2 parts. Part 1 will evaluate safety and efficacy of two different doses …
- Stage
- Phase 2
- Ages
- 18 and older
- Site
- Northside Hospital, Atlanta, Georgia
- Locations
- 83 in total
- Run by
- Kartos Therapeutics, Inc.
How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.
What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.
Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.